Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 2
2004 7
2005 3
2006 3
2007 4
2008 6
2009 8
2010 9
2011 11
2012 16
2013 18
2014 20
2015 16
2016 20
2017 16
2018 19
2019 16
2020 19
2021 27
2022 28
2023 11
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Results by year

Filters applied: . Clear all
Page 1
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries.
Sharmin S, Roos I, Malpas CB, Iaffaldano P, Simone M, Filippi M, Kubala Havrdova E, Ozakbas S, Brescia Morra V, Alroughani R, Zaffaroni M, Patti F, Eichau S, Salemi G, Di Sapio A, Inglese M, Portaccio E, Trojano M, Amato MP, Kalincik T; Writing Group; Italian Multiple Sclerosis and Related Disorders Register and MSBase Study Group. Sharmin S, et al. Lancet Child Adolesc Health. 2024 May;8(5):348-357. doi: 10.1016/S2352-4642(24)00047-6. Epub 2024 Mar 25. Lancet Child Adolesc Health. 2024. PMID: 38547883
Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience.
Ruggieri S, Ianniello A, Copetti M, Altieri M, Buscarinu MC, Centonze D, Cortese A, De Giglio L, Fantozzi R, Gasperini C, Grimaldi LME, Landi D, Marfia GA, Mirabella M, Nistri R, Nociti V, Oddo O, Romano S, Salemi G, Tortorella C, Pozzilli C, Petracca M. Ruggieri S, et al. Among authors: pozzilli c. Neurotherapeutics. 2024 Apr;21(3):e00338. doi: 10.1016/j.neurot.2024.e00338. Epub 2024 Feb 26. Neurotherapeutics. 2024. PMID: 38413275 Free PMC article.
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
Iaffaldano P, Lucisano G, Guerra T, Patti F, Cocco E, De Luca G, Brescia Morra V, Pozzilli C, Zaffaroni M, Ferraro D, Gasperini C, Salemi G, Bergamaschi R, Lus G, Inglese M, Romano S, Bellantonio P, Di Monte E, Maniscalco GT, Conte A, Lugaresi A, Vianello M, Torri Clerici VLA, Di Sapio A, Pesci I, Granella F, Totaro R, Marfia GA, Danni MC, Cavalla P, Valentino P, Aguglia U, Montepietra S, Ferraro E, Protti A, Spitaleri D, Avolio C, De Riz M, Maimone D, Cavaletti G, Gazzola P, Tedeschi G, Sessa M, Rovaris M, Di Palma F, Gatto M, Cargnelutti D, De Robertis F, Logullo FO, Rini A, Meucci G, Ardito B, Banfi P, Nasuelli D, Paolicelli D, Rocca MA, Portaccio E, Chisari CG, Fenu G, Onofrj M, Carotenuto A, Ruggieri S, Tortorella C, Ragonese P, Nica M, Amato MP, Filippi M, Trojano M; Italian MS Register. Iaffaldano P, et al. Among authors: pozzilli c. J Neurol. 2024 Mar;271(3):1150-1159. doi: 10.1007/s00415-023-12137-8. Epub 2023 Dec 22. J Neurol. 2024. PMID: 38135850
Multiple Sclerosis Progression and Relapse Activity in Children.
Iaffaldano P, Portaccio E, Lucisano G, Simone M, Manni A, Guerra T, Paolicelli D, Betti M, De Meo E, Pastò L, Razzolini L, Rocca MA, Ferrè L, Brescia Morra V, Patti F, Zaffaroni M, Gasperini C, De Luca G, Ferraro D, Granella F, Pozzilli C, Romano S, Gallo P, Bergamaschi R, Coniglio MG, Lus G, Vianello M, Banfi P, Lugaresi A, Totaro R, Spitaleri D, Cocco E, Di Palma F, Maimone D, Valentino P, Torri Clerici V, Protti A, Maniscalco GT, Salemi G, Pesci I, Aguglia U, Lepore V, Filippi M, Trojano M, Amato MP; Italian Multiple Sclerosis Register. Iaffaldano P, et al. Among authors: pozzilli c. JAMA Neurol. 2024 Jan 1;81(1):50-58. doi: 10.1001/jamaneurol.2023.4455. JAMA Neurol. 2024. PMID: 38010712
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
Bisecco A, Matrone F, Capobianco M, De Luca G, Filippi M, Granella F, Lus G, Marfia GA, Mirabella M, Patti F, Trojano M, Mascolo A, Copetti M, Tedeschi G, Gallo A; OCREVID study group on behalf of the Italian MS Register. Bisecco A, et al. J Neurol. 2024 Feb;271(2):699-710. doi: 10.1007/s00415-023-12084-4. Epub 2023 Nov 20. J Neurol. 2024. PMID: 37982852 Free PMC article.
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.
Ruggieri S, Prosperini L, Al-Araji S, Annovazzi PO, Bisecco A, Ciccarelli O, De Stefano N, Filippi M, Fleischer V, Evangelou N, Enzinger C, Gallo A, Garjani A, Groppa S, Haggiag S, Khalil M, Lucchini M, Mirabella M, Montalban X, Pozzilli C, Preziosa P, Río J, Rocca MA, Rovira A, Stromillo ML, Zaffaroni M, Tortorella C, Gasperini C; MAGNIMS Study Group. Ruggieri S, et al. Among authors: pozzilli c. J Neurol Neurosurg Psychiatry. 2024 Jan 11;95(2):142-150. doi: 10.1136/jnnp-2023-331920. J Neurol Neurosurg Psychiatry. 2024. PMID: 37775266
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
Coles AJ, Achiron A, Traboulsee A, Singer BA, Pozzilli C, Oreja-Guevara C, Giovannoni G, Comi G, Freedman MS, Ziemssen T, Shiota D, Rawlings AM, Wong AT, Chirieac M, Montalban X. Coles AJ, et al. Among authors: pozzilli c. Ther Adv Neurol Disord. 2023 Sep 21;16:17562864231194823. doi: 10.1177/17562864231194823. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37745914 Free PMC article.
The added value of spinal cord lesions to disability accrual in multiple sclerosis.
Ruggieri S, Prosperini L, Petracca M, Logoteta A, Tinelli E, De Giglio L, Ciccarelli O, Gasperini C, Pozzilli C. Ruggieri S, et al. Among authors: pozzilli c. J Neurol. 2023 Oct;270(10):4995-5003. doi: 10.1007/s00415-023-11829-5. Epub 2023 Jun 29. J Neurol. 2023. PMID: 37386292 Free PMC article.
243 results